ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ESPR Esperion Therapeutics Inc

2.13
-0.12 (-5.33%)
Last Updated: 13:41:15
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,060,589
Bid Price 2.13
Ask Price 2.14
News -
Day High 2.265

Low
0.70

52 Week Range

High
3.40

Day Low 2.12
Share Name Share Symbol Market Stock Type
Esperion Therapeutics Inc ESPR NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.12 -5.33% 2.13 13:41:15
Open Price Low Price High Price Close Price Previous Close
2.25 2.12 2.265 2.25
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
11,344 4,060,589 US$ 2.16 US$ 8,778,135 - 0.70 - 3.40
Last Trade Type Quantity Price Currency
13:41:28 5 US$ 2.127 USD

Esperion Therapeutics (ESPR) Options Flow Summary

Overall Flow

Bullish

Net Premium

92k

Calls / Puts

100.00%

Buys / Sells

200.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Esperion Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
394.16M 185.05M - 116.33M -209.25M -1.13 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Esperion Therapeutics News

Date Time Source News Article
5/23/202408:00GlobeNewswire Inc.Esperion to Participate in Upcoming June Investor..
5/22/202407:00GlobeNewswire Inc.First-In-Class Cholesterol-Lowering Treatment NILEMDO®..
5/20/202415:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/20/202405:00GlobeNewswire Inc.Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in..
5/17/202414:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/14/202407:00GlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic..
5/10/202415:00GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing..
5/08/202415:31Edgar (US Regulatory)Form 8-K - Current report
5/07/202407:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/07/202406:29Edgar (US Regulatory)Form 8-K - Current report
5/07/202405:00GlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial Results
4/29/202407:00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor Conferences
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ESPR Message Board. Create One! See More Posts on ESPR Message Board See More Message Board Posts

Historical ESPR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.602.632.122.377,107,368-0.47-18.08%
1 Month2.012.631.882.278,383,0150.125.97%
3 Months2.523.401.712.407,591,455-0.39-15.48%
6 Months1.243.401.16012.356,848,9070.8971.77%
1 Year1.633.400.701.985,096,3630.5030.67%
3 Years21.0026.770.703.522,838,612-18.87-89.86%
5 Years51.3779.9890.708.081,951,557-49.24-95.85%

Esperion Therapeutics Description

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Your Recent History

Delayed Upgrade Clock